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a molecule-dependent target speciﬁ  c-
ity: mutations in parC are generally 
selected by peﬂ  oxacin, ciproﬂ  oxacin, 
and levoﬂ  oxacin, and those in gyrA 
are selected by sparﬂ  oxacin, gatiﬂ  oxa-
cin, moxiﬂ  oxacin, gemiﬂ  oxacin, and 
garenoxacin (5). In second-step mu-
tants, mutations are present in both 
parC and gyrA and confer resistance 
to the antistreptococcal FQs levoﬂ  ox-
acin, moxiﬂ  oxacin, and gatiﬂ  oxacin. 
FQ resistance in GBS has been 
reported in Japan, the United States, 
and Spain (6–8). Up to now, all FQ-
resistant GBS strains described were 
highly resistant because of point muta-
tions in gyrA and parC QRDR; a parC 
mutation at position 79 was present 
in all strains. These strains were iso-
lated from elderly adults who, in some 
cases, had received quinolone therapy. 
Low-level resistance to FQ in GBS 
CNR0717 was associated with a Ser 
79 → Tyr mutation in parC. There-
fore, although the FQ sensitivity of 
this strain is unknown, a ﬁ  rst-step mu-
tant could have been selected in vivo 
as our patient was treated with levo-
ﬂ  oxacin for 2 weeks. 
GBS is an unusual cause of acute 
bacterial exacerbation of chronic bron-
chitis compared with other respiratory 
pathogens such as S. pneumoniae, but 
pathologies associated with this bacte-
rium are changing. Clinical microbiol-
ogists should be aware of these chang-
es and test isolates of Streptococcus 
spp. for susceptibility to FQs. This 
report indicates that FQ resistance 
among streptococci is a growing con-
cern and that levoﬂ  oxacin can select in 
vivo parC ﬁ  rst-step mutants that will 
facilitate emergence of high-level FQ-
resistant GBS strains, as demonstrated 
in vitro for S. pneumoniae (9). Finally, 
although FQ treatment is recommend-
ed for high-risk groups with acute 
exacerbations of chronic bronchitis, 
these antimicrobial drugs must be re-
served for situations in which there are 
no effective alternative drugs to treat 
infections caused by multidrug-resis-
tant bacteria. For susceptible strains, 
β-lactams, which still constitute the 
ﬁ  rst-line recommended antimicrobial 
drugs, should be used for treatment of 
these patients (10).
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Dengue and Relative 
Bradycardia
To the Editor: In a recent letter 
to Emerging Infectious Diseases, La-
teef and colleagues identiﬁ  ed a rela-
tionship between dengue and relative 
bradycardia in patients in Singapore. 
They stated that “To our knowledge, 
this sign has not been previously as-
sociated with dengue” (1). Unfortu-
nately, the association of dengue fever 
with relative bradycardia has already 
been well established and is certainly 
not a new ﬁ  nding (2,3). Despite this, 
however, there is no harm done in re-
inforcing an often forgotten clinical 
sign that can assist in the diagnosis of 
dengue, especially in those countries 
with limited resources.
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Importation of 
Poliomyelitis by 
Travelers
To the Editor: In July 2007, an 
Australian traveler imported polio 
from Pakistan to Australia (1). He 
was a 22-year-old man who had im-
migrated to Australia and had traveled 
to his country of origin (Pakistan) to 
visit friends and relatives. Pakistan is 
one of 4 countries (Afghanistan, In-
dia, Nigeria, Pakistan) where polio is 
still endemic. A diagnosis of polio was 
made shortly after his return to Aus-
tralia. Australia was certiﬁ  ed as polio-
free in 2000. Australia will not be the 
last industrialized country affected by 
importation of polio. All countries are 
at risk until polio has been completely 
eradicated.
Between 2003 and 2006, polio 
was imported by travelers (e.g., refu-
gees, pilgrims, traders) to 24 polio-free 
countries (2). The origin of these im-
portations was largely the 4 countries 
where polio transmission was never 
completely interrupted. The importa-
tions resulted in about 1,400 second-
ary cases (2). The resurgence of polio 
by international spread was a setback 
to the Global Polio Eradication Initia-
tive that had successfully decreased 
the number of polio-affected countries 
to only 9 in 2002.
The revised International Health 
Regulations, IHR (2005) (3), entered 
into legal force on June 15, 2007. 
These regulations provide the legal 
framework for coordination of the 
international effort to reduce or pre-
vent international spread of diseases 
of public health concern. IHR (2005) 
(2) lists polio as one of the diseases of 
public health emergencies of interna-
tional concern. Preventing importa-
tion of polio into polio-free countries 
is therefore a test case for the revised 
International Health Regulations (4). 
Compared to the previous IHR (1969), 
IHR (2005) has moved away from the 
deﬁ  nition  of  ﬁ   xed maximum mea-
sures relating to speciﬁ  c diseases and 
instead focuses on the issuance of con-
text-speciﬁ  c recommendations, made 
either on a temporary emergency ba-
sis (a temporary recommendation) or 
routinely for established ongoing risks 
of disease spread (a standing recom-
mendation). 
One strategy to protect polio-free 
countries from reintroduction of wild 
poliovirus is by requiring proof of po-
lio vaccination for all incoming trav-
elers from polio-endemic countries. 
This was proposed by the Advisory 
Committee on Poliomyelitis Eradica-
tion in October 2006. The rationale is 
similar to that used for yellow fever, 
currently the only disease for which 
proof of vaccination may be required 
for travelers as a condition of en-
try to a country. The proposal of the 
Advisory Committee of Poliomyeli-
tis Eradication was discussed at the 
World Health Assembly in May 2007 
(5). Although the main strategy for po-
lio eradication continues to be attain-
ing high vaccination coverage against 
polio in all countries, the 193 member 
states have also adopted the resolution 
to “continue to examine and dissemi-
nate measures that member states can 
take for reducing the risk and con-
sequences of international spread of 
polioviruses, including, if and when 
needed, the consideration of Tempo-
rary or Standing Recommendations, 
under the International Health Regu-
lations (2005)” (3).
The recent polio importation by 
an inadequately vaccinated traveler 
would add impetus to such consider-
ations. However, this case also shows 
that focusing on travelers from po-
lio-endemic countries alone may not 
be sufﬁ   cient. Immigrants from de-
veloping countries to industrialized 
countries who subsequently return to 
their home countries to visit friends 
and relatives may also be at increased 
risk if traveling to polio-endemic 
countries, in particular as many may 
not have received adequate child-
hood vaccination including vaccina-
tion against polio (6). Targeting those 
visiting friends and relatives is there-
fore a potential additional strategy 
to reduce the risk for the worldwide 
spread of polio. 
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